Metastatic recurrence in colorectal cancer arises from residual EMP1 + cells.

Autor: Cañellas-Socias A; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Cortina C; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Hernando-Momblona X; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Palomo-Ponce S; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Mulholland EJ; Gastrointestinal Stem Cell Biology Lab, Wellcome Centre Human Genetics, University of Oxford, Oxford, UK., Turon G; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Mateo L; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Conti S; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Roman O; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Sevillano M; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Slebe F; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Stork D; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Caballé-Mestres A; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Berenguer-Llergo A; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Álvarez-Varela A; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Fenderico N; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Novellasdemunt L; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Jiménez-Gracia L; CNAG-CRG, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Sipka T; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Bardia L; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Lorden P; CNAG-CRG, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Colombelli J; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Heyn H; CNAG-CRG, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain., Trepat X; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Tejpar S; Digestive Oncology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium., Sancho E; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Tauriello DVF; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Leedham S; Gastrointestinal Stem Cell Biology Lab, Wellcome Centre Human Genetics, University of Oxford, Oxford, UK.; Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.; Oxford National Institute for Health Research Biomedical Research Centre, Oxford, UK., Attolini CS; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Batlle E; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. eduard.batlle@irbbarcelona.org.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. eduard.batlle@irbbarcelona.org.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. eduard.batlle@irbbarcelona.org.
Jazyk: angličtina
Zdroj: Nature [Nature] 2022 Nov; Vol. 611 (7936), pp. 603-613. Date of Electronic Publication: 2022 Nov 09.
DOI: 10.1038/s41586-022-05402-9
Abstrakt: Around 30-40% of patients with colorectal cancer (CRC) undergoing curative resection of the primary tumour will develop metastases in the subsequent years 1 . Therapies to prevent disease relapse remain an unmet medical need. Here we uncover the identity and features of the residual tumour cells responsible for CRC relapse. An analysis of single-cell transcriptomes of samples from patients with CRC revealed that the majority of genes associated with a poor prognosis are expressed by a unique tumour cell population that we named high-relapse cells (HRCs). We established a human-like mouse model of microsatellite-stable CRC that undergoes metastatic relapse after surgical resection of the primary tumour. Residual HRCs occult in mouse livers after primary CRC surgery gave rise to multiple cell types over time, including LGR5 + stem-like tumour cells 2-4 , and caused overt metastatic disease. Using Emp1 (encoding epithelial membrane protein 1) as a marker gene for HRCs, we tracked and selectively eliminated this cell population. Genetic ablation of EMP1 high cells prevented metastatic recurrence and mice remained disease-free after surgery. We also found that HRC-rich micrometastases were infiltrated with T cells, yet became progressively immune-excluded during outgrowth. Treatment with neoadjuvant immunotherapy eliminated residual metastatic cells and prevented mice from relapsing after surgery. Together, our findings reveal the cell-state dynamics of residual disease in CRC and anticipate that therapies targeting HRCs may help to avoid metastatic relapse.
(© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: